NEWS AND RESOURCES
Efficacy Assessment of SF001, a Next Generation Polyene
Antifungal in a Neutropenic Mouse Model of Invasive Fusariosis.
Gebremariam T, et al. Presented at Clinical Mycology Today, the
biennial meeting of the MSGERC. September 4-6, 2024; Colorado Springs,
CO.
SF001, a Novel Micellar Polyene, Demonstrates a Prolonged
Post-antifungal Effect In vitro against Yeast.
Hufnagel D, et al. Presented at ESCMID Global 2024. April 27-30, 2024;
Barcelona, Spain.
Inoculum Density has an Impact on SF001 Fungicidal Activity
againstCandida albicans.
Hufnagel D, et al. Presented at ESCMID Global 2024. April 27-30, 2024;
Barcelona, Spain.
Front-Loaded Exposures Increase the Fungicidal Effect of
SF001: A Basis for Infrequent Dosing Regimens.
VanScoy BD, et al. Presented at ESCMID Global 2024. April 27-30, 2024;
Barcelona, Spain.
Efficacy assessment of SF001, a next-generation polyene
antifungal, in the immunosuppressed mouse model of invasive pulmonary
aspergillosis and mucormycosis.
Gebremariam T, et al. Presented at the 11th AAAM conference. January
20-23, 2024; Milan, Italy.
SF001: a next-generation, long acting, polyene antifungal
with reduced nephrotoxicity.
Marr K. Presented at the 11th AAAM conference. January 20-23, 2024;
Milan, Italy.
Tuning sterol extraction kinetics yields a renal sparing
polyene antifungal.
Maji, A., Soutar, C.P., Zhang, J. et al. Nature 623, 1079-1085
[2023]. https://doi.org/10.1038/s41586-023-06710-4.
Efficacy assessment of SF001, a third-generation polyene
antifungal, in the immunosuppressed mouse model of invasive pulmonary
aspergillosis.
Gebremariam T, et al. Presented at the 11th TIMM conference. October
20-23, 2023; Athens, Greece.
A 3rd generation renal sparing polyene antifungal.
Burke MD. Presented at Clinical Mycology Today, the biennial
meeting of the MSGERC. September 7-9, 2022; Albuquerque, NM.
An evaluation of SF001 pharmacokinetics-pharmacodynamics
using a neutropenic mouse disseminated candidiasis model.
VanScoy BD et al. Presented at Clinical Mycology Today, the
biennial meeting of the MSGERC. September 7-9, 2022; Albuquerque,
NM.
Comparative in vivo activity of SF001 in neutropenic models
of invasive fungal infection.
Andes DR et al. Presented at Clinical Mycology Today, the
biennial meeting of the MSGERC. September 7-9, 2022; Albuquerque,
NM.
Development of resistance to SF001, a next generation polyene
antifungal.
Pillar C et al. Presented at Clinical Mycology Today, the
biennial meeting of the MSGERC. September 7-9, 2022; Albuquerque,
NM.
Efficacy assessment of SF001, a next generation polyene
antifungal, in the neutropenic mouse model of pulmonary
mucormycosis.
Gebremariam T et al. Presented at Clinical Mycology Today, the
biennial meeting of the MSGERC. September 7-9, 2022; Albuquerque,
NM.
In vitro activity of SF001, a next generation polyene
antifungal, against yeasts and moulds.
Pillar C et al. Presented at Clinical Mycology Today, the
biennial meeting of the MSGERC. September 7-9, 2022; Albuquerque,
NM.
Selective tuning of sterol extraction kinetics yields renal
sparing antifungal.
Maji A et al. Presented at Clinical Mycology Today, the
biennial meeting of the MSGERC. September 7-9, 2022; Albuquerque,
NM.
Structural understanding of renal sparing amphotericin B
derivatives.
Soutar C et al. Presented at Clinical Mycology Today, the
biennial meeting of the MSGERC. September 7-9, 2022; Albuquerque,
NM.
The next generation polyene SF001 demonstrates broad-spectrum
antifungal activity against yeasts, moulds, and endemic
fungi.
Wiederhold NP et al. Presented at Clinical Mycology Today, the biennial
meeting of the MSGERC. September 7-9, 2022; Albuquerque, NM.
AAAM=Advances Against Aspergillosis & Mucormycosis; ESCMID=European Society of Clinical Microbiology and Infectious Diseases; MSGERC=Mycoses Study Group Education and Research Consortium; TIMM=Trends in Medical Mycology.
